Product category:
Cell/tissue handling and counting
News Release from: Microbix Biosystems
Edited by the Laboratorytalk Editorial
Team on 30 August 2002
Successful third quarter
Microbix Biosystems reports profitable third quarter and 19% rise in sales
Microbix Biosystems has reported a profitable third quarter ended 30 June 2002 with a rise in sales over the same period last year The company reported sales of $870,022 compared to $726,547 for the same period in 2001, a 19.7% increase
This article was originally published on Laboratorytalk on 20 Mar 2003 at 8.00am (UK)
Related stories
Double anniversary at Focus
Supplier of one quarter of the world's haematology analysers celebrates its twentieth birthday, while its parent company celebrates its fiftieth
Merger of HTP operations
"With a combined instrumentation and biochemistry team we can respond faster and more flexibly to the assaying demands of current and future customers"
Net income increased marginally as foreign exchange losses and costs associated with the company's biotherapeutics licensing efforts negatively affected the quarter.
Microbix stated that its cash position, down for the quarter, is expected to improve in the fourth quarter with the collection of above-average levels of customer receivables.
Licensing discussions and interest in thecCompany's plans to market generic urokinase continued during the quarter with news of Abbott Laboratories's plans to re-launch Abbokinase plus strong messages from the US Food and Drug Administration regarding the approval path for generic biotherapeutics.
"In the core business, we are starting to see results from our efforts to expand product lines and reduce the impact of the cyclical nature of some of the market sectors in which we operate.
This core platform continues to fund our development team which is creating new higher value products and technologies such as urokinase," said William Gastle, president and CEO.
"As expected, we are seeing steady performance in the second half of this year and are anticipating significant new developments in technology and products that should underpin strong growth going forward." Microbix specialises in developing and manufacturing cell culture-derived biologics for an emerging world market of biotherapeutic drugs and vaccines.
It makes reagents for building diagnostic products and tools used in biotechnology research.
• Microbix Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
